Relay Therapeutics Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform, which integrates computational modeling, machine learning, and experimental approaches to target dynamic protein motions for small molecule therapeutics. The company specializes in oncology and genetic diseases, with its lead candidate RLY-2608 (zovegalisib), a pan-mutant and isoform-selective PI3Kα inhibitor in clinical development for PI3Kα-mutated HR+/HER2- metastatic breast cancer, solid tumors, and vascular malformations, often in combination with fulvestrant or CDK4/6 inhibitors. Additional programs include an αGal chaperone for Fabry disease, RLY-8161 targeting NRAS-driven tumors, and RLY-1013 as an estrogen receptor alpha degrader. Relay Therapeutics Inc. maintains collaborations with partners like D. E. Shaw Research for computational target analysis, Elevar Therapeutics for lirafugratinib (RLY-4008) in FGFR2-driven cancers, and Pfizer for combination therapies. Founded in 2015 and headquartered in Cambridge, Massachusetts, it plays a key role in advancing precision oncology by addressing challenging protein targets to develop potentially transformative treatments.